Evidence map›Paper›PMID 28359881›Full record

ArticleBehavioural brain research2017

KU32 prevents 5-fluorouracil induced cognitive impairment.

Michael J Sofis, David P Jarmolowicz, Sam V Kaplan, Rachel C Gehringer, Shea M Lemley, Gaurav Garg, Brian S Blagg, Michael A Johnson

Abstract read
In one paragraph

Article in Behavioural brain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michael J SofisDepartment of Applied Behavioral Science, University of Kansas, 4041 Dole Developmental Center, 1000 Sunnyside Ave., Lawrence, KS 66045, USA. Electronic address: sofis@ku.edu.
David P JarmolowiczDepartment of Applied Behavioral Science, University of Kansas, 4041 Dole Developmental Center, 1000 Sunnyside Ave., Lawrence, KS 66045, USA. Electronic address: dpj@ku.edu.
Sam V KaplanDepartment of Chemistry, University of Kansas, 2919 Malott Hall, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
Rachel C GehringerDepartment of Chemistry, University of Kansas, 2919 Malott Hall, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
Shea M LemleyDepartment of Applied Behavioral Science, University of Kansas, 4041 Dole Developmental Center, 1000 Sunnyside Ave., Lawrence, KS 66045, USA.
Gaurav GargDepartment of Medicinal Chemistry, University of Kansas, 4070 Malott Hall, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
Brian S BlaggDepartment of Medicinal Chemistry, University of Kansas, 4070 Malott Hall, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
Michael A JohnsonDepartment of Chemistry, University of Kansas, 2919 Malott Hall, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
University of Kansas · US

Funding

Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LUNTE, SUSAN M · 2012 to 2021
$22.1M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BROOKS, WILLIAM M. · 2011 to 2020
$16.6M
Chaperone therapeutics for the treatment of DPNR01NS075311 · NINDS · UNIVERSITY OF NOTRE DAME · PI BLAGG, BRIAN S J, DOBROWSKY, RICK T · 2012 to 2020
$2.8M
Methods for Measuring Sub-second Neurotransmitter InteractionsR21NS077485 · NINDS · UNIVERSITY OF KANSAS LAWRENCE · PI JOHNSON, MICHAEL A. · 2012 to 2013
$396k
NIA NIH HHS P30 AG035982NIGMS NIH HHS P20 GM103638NINDS NIH HHS R01 NS075311NINDS NIH HHS R21 NS077485
6 · The paper itself

Abstract

Chemotherapy induced cognitive impairment (i.e. chemobrain) involves acute and long-term deficits in memory, executive function, and processing speed. Animal studies investigating these cognitive deficits have had mixed results, potentially due to variability in the complexity of behavioral tasks across experiments. Further, common chemotherapy treatments such as 5-fluorouracil (5-FU) break down myelin integrity corresponding to hippocampal neurodegenerative deficits and mitochondrial dysfunction. There is little evidence, however, of pharmacological treatments that may target mitochondrial dysfunction. Using a differential reinforcement of low rates (DRL) task combining spatial and temporal components, the current study evaluated the preventative effects of the pharmacological agent KU32 on the behavior of rats treated with 5-FU (5-FU+Saline vs. 5FU+KU32). DRL performance was analyzed the day after the first set of injections (D1), the day after the second set of injections (D7) and the last day of the experiment (D14). The 5FU+KU32 group earned significantly more reinforcers on the DRL task at D7 and D14 than the 5FU+Saline group. Further, the 5FU+KU32 group showed significantly better temporal discrimination. The 5FU+KU32 showed within-group improvement in temporal discrimination from D7 to D14. No significant differences were observed in spatial discrimination, however, those in the 5FU+Saline group responded more frequently on T3 compared to the 5FU+KU32 group, highlighting temporal discrimination differences between groups. The current data suggest that KU32 shows promise in the prevention of chemotherapy induced impairments in temporal discrimination.

Indexed as

Analysis of VarianceAnimalsCognition DisordersDisease Models, AnimalFluorouracilImmunosuppressive AgentsNeuroprotective AgentsNovobiocinRatsRats, WistarTime FactorsFluorouracilImmunosuppressive AgentsKU-32 compoundNeuroprotective AgentsNovobiocinChemobrainCognitive impairmentInhibitionKU32Temporal discriminationTiming

Identifiers

PMID28359881
PMCPMC5846472
OpenAlexW2601878845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.